[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562299":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":23,"collaborators":7,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":31,"acronym":32,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":7,"studyType":40,"phases":7,"briefSummary":41,"conditions":42,"keywords":44,"overallStatus":45,"whyStopped":7,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":7},{"fullName":5,"class":6},"Assiut University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","Fibroscan","Fibroscan (transient elastography ) is a non-invasive imaging method that evaluates steatosis and fibrosis by measuring liver stiffness using ultrasonographic sound waves. It is an acceptable alternative to liver biopsy and is fast , reliable, and reproducible, enabling screening and disease follow-up.11 It is now widely used to assess liver fibrosis in various liver diseases; however, currently there is no data on Fibroscan assessment regarding hepatic involvement in SLE patients. The aim of this study was to evaluate fatty liver and liver fibrosis in SLE patients using fibroscan and determine associated factors such as immunosuppressive medications.",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Ayman Makram Ayad, physician","CONTACT","+20 01070387266","Aimen.16266102@med.aun.edu.eg",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Mohammad Alyamany kobeisy, prof","01002228914","Yamany1@med.aun.edu.eg",{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Ayman Makram Ayad Souliman","physician","100562299","studying-non-alcoholic-fatty-liver-disease-and-liver-fibrosis-among-systemic-lupus-erythematosus-patients-at-assiut-university-hospital-100562299",false,"NCT06601361","Studying Non Alcoholic Fatty Liver Disease and Liver Fibrosis Among Systemic Lupus Erythematosus Patients at Assiut University Hospital","NAFLD and SLE","Inclusion Criteria:\n\n* Adult patients aged 18 years old ,Both sex male and female, diagnosed with SLE\n\nExclusion Criteria:\n\n1. Age below 18 years old\n2. patients with hepatitis b virus (HBV), hepatitis c virus (HCV) or cirrhosis\n3. malignancy, cardiac disease,\n4. patients on dialysis.\n5. obese patient, BMI more than 30","ALL","18 Years","75 Years",{"count":38,"type":39},112,"ESTIMATED","OBSERVATIONAL","Aim of the study :-\n\n1. to estimate prevalence of non alcoholic fatty liver disease and liver fibrosis among Systemic lupus erythematosus patients\n2. to determine risk factors in SLE patients contributing to NAFLD and liver fibrosis",[43],"NAFLD - Nonalcoholic Fatty Liver Disease",[32],"NOT_YET_RECRUITING","2024-09-14",{"date":48,"type":49},"2024-09-19","ACTUAL",{"date":51,"type":39},"2024-10-01",{"date":53,"type":39},"2025-12",{"name":5,"class":6}]